Home  »  News   »  Summarizing The Case For Hecla Mining Company (HL)...

Summarizing The Case For Hecla Mining Company (HL), BioNTech SE (BNTX)

Hecla Mining Company (NYSE: HL) shares are 74.04% up in the year-to-date (YTD) period and have moved 3.51% or $0.2 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +321.43% lower. Comparatively, the stock is -13.11% down YTD and 64.35% over the trailing 3-month period. If we look at the shorter duration, its week performance is 1.55% and 10.28% over the month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Analyst Recommendations

On July 17, 2020, RBC Capital Mkts recommended the HL stock is a Sector Perform, while earlier, BofA Securities had Upgrade the stock as a Neutral on August 05, 2020. 11 analysts offering the recommendations for the stock have a consensus rating of 2.70 to suggest that the HL stock is a “Moderate Buy. 0 of the 11 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 4 recommend buying, with 0 rating it as an Overweight.

The stock currently trades at $5.90 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $5.90. The forecasts give the Hecla Mining Company stock a price target range of $7.25 on the higher side while at least one analyst think the stock could plunge to a low of $4.00. The two limits represent an upside potential of 18.62% or -47.5%.

Earnings Forecast

For the current year, earnings should grow to an average of $0, up 1.40% from -$0.13 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.03 and $0.08. Wall Street estimates earnings per share to be at an average of $0.25 for the next year.

Insider Transactions Summary

According to SEC data, total insider shares purchases at the company stands at 25 over the last 12 months, while SEC filings reveal that there have been 8 insider sales over the same period. Insiders have purchases 2,160,840 shares while those sold by company executives and officers stand at 460,100. The last 3 months have seen insiders trade a total of 850,021 and 309,858 in purchases and sales respectively.

Sienko David C, a VP & General Counsel at the company, sold 75,000 shares worth $0.45 million at $6.01 per share on Aug 13. The Director had earlier sold another 35,000 HL shares valued at $0.21 million on Aug 13. The shares were sold at $5.96 per share. Brown Robert Denis (VP – Corporate Development) sold 172,000 shares at $5.80 per share on Aug 12 for a total of $1.0 million while Rogers Terry V, (Director) sold 17,300 shares on Jan 08 for $57419.0 with each share fetching $3.32.

BioNTech SE (NASDAQ:BNTX), on the other hand, is trading around $64.00 with a market cap of $15.62B and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $76.99 and spell out a more modest performance – a 16.87% return. Some analysts are even forecasting -$0.36 per share in earnings this year on a short term (1 year) basis.

Let us briefly look at the BioNTech SE (BNTX) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.

Company balance sheet and cash flow

BNTX’s operating expenses over the recent quarter were at $129.11 million. This represented a -180.77% of the company’s total revenues which amounted $45.98 million.

In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $1.07 billion from $807.77 million over the previous quarter. Short term investments amounted to $2.15 million while total current assets were at $683.91 million. The cash flow from operating activities totaled -$77.31 million, significantly lower than the -$68.71 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$100.86 million.

Major holders

Insiders own 1.26% of the company shares, while shares held by institutions stand at 11.40% with a share float percentage of 220.45M. Investors are also buoyed by the number of investors in a company, with BioNTech SE having a total of 36 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 10.21 million shares worth more than $681.47 million. As of Jun 29, 2020, FMR, LLC held 77.35% of shares outstanding.

The other major institutional holder is Redmile Group, LLC, with the investment firm holding over 3.07 million shares as of Jun 29, 2020. The firm’s total holdings are worth over $204.84 million and represent 23.25% of shares outstanding.

Related Posts




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam